Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Lipoglycopeptide Antibacterial [EPC]

Known as: Lipoglycopeptide Antibacterial 
 
National Institutes of Health

Related topics

Related topics

3 relations
Anti-Bacterial AgentsBacterial InfectionsLipoglycopeptides [Chemical/Ingredient]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Engineered biosynthesis of enduracidin lipoglycopeptide antibiotics using the ramoplanin mannosyltransferase Ram29
The lipopeptides ramoplanin from Actinoplanes sp. ATCC 33076 and enduracidin produced by Streptomyces fungicidicus are effective… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Review
2013
Review
2013
Oritavancin - a new semisynthetic lipoglycopeptide agent to tackle the challenge of resistant gram positive pathogens.
Natural glycopeptide antibiotics like vancomycin and teicoplanin have played a significant role in countering the threat posed by… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 3
2013
2013
Studies on the mechanism of telavancin decreased susceptibility in a laboratory-derived mutant.
Telavancin is a novel semisynthetic lipoglycopeptide derivative of vancomycin with a dual mode of action. This study sought to… Expand
2011
2011
Synthesis and characterization of the arylomycin lipoglycopeptide antibiotics and the crystallographic analysis of their complex with signal peptidase.
Glycosylation of natural products, including antibiotics, often plays an important role in determining their physical properties… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE